(IDPT) Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases
Related Questions
What does this partial response mean for the progression of INDPT's Decoy20 program and potential FDA filing timeline?
How does the observed response compare to existing therapies for urothelial cancer and potential market share?
Will this data point lead to a re‑rating of the stock or trigger any partnership or licensing activity?